MedTrace Logo

Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

NCT02881008 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-09-19

Study results available
· View outcomes & findings →

Summary

A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.

Conditions

Interventions

DRUG

Entecavir

DRUG

Myrcludex B

Sponsors & Collaborators

  • Hepatera Ltd.

    lead INDUSTRY

Principal Investigators

  • Pavel Bogomolov, PhD · LLC "Clinical Hospital of Tsentrosoyuz"

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-14
Primary Completion
2014-10-04
Completion
2014-10-04

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02881008 on ClinicalTrials.gov